Pfizer Cooperating With Lipitor Marketing Probe
- Share via
Pfizer Inc. said it was cooperating with a federal investigation into whether it had been improperly marketing cholesterol-lowering drug Lipitor, the world’s top-selling medicine.
The investigation was disclosed Tuesday in the Wall Street Journal. The policy of the U.S. attorney’s office in New York is to neither confirm nor deny any probe, a spokesman there said.
Similar concerns were raised in a federal lawsuit filed Monday by a union insurance plan alleging that New York-based Pfizer had been improperly marketing Lipitor for “off-label” use, costing drug plans billions of dollars in unwarranted prescriptions. Off-label uses are those not approved by the Food and Drug Administration, although doctors are not barred from prescribing drugs for such uses.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
